Hybrid molecules based on 1,3,5-triazine as potential therapeutics: A focused review.

Prasher, P; Sharma, M; Aljabali, AAA; Gupta, G; Negi, P; Kapoor, DN; Singh, I; Zacconi, FC; de Jesus Andreoli Pinto, T; da Silva, MW; Bakshi, HA; Chellappan, DK; Tambuwala, MM; Dua, K

Hybrid molecules based on 1,3,5-triazine as potential therapeutics: A focused review.

Prasher, P Sharma, M Aljabali, AAA Gupta, G Negi, P Kapoor, DN Singh, I Zacconi, FC de Jesus Andreoli Pinto, T da Silva, MW Bakshi, HA Chellappan, DK Tambuwala, MM Dua, K

Permalink

Publisher:: Wiley
Publication Type:: Journal Article
Citation:: Drug development research, 2020, 81, (7), pp. 837-858
Issue Date:: 2020-11

Closed Access

	Filename	Description	Size
	ddr.21704.pdf		3 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Prasher, P
dc.contributor.author	Sharma, M
dc.contributor.author	Aljabali, AAA
dc.contributor.author	Gupta, G
dc.contributor.author	Negi, P
dc.contributor.author	Kapoor, DN
dc.contributor.author	Singh, I
dc.contributor.author	Zacconi, FC
dc.contributor.author	de Jesus Andreoli Pinto, T
dc.contributor.author	da Silva, MW
dc.contributor.author	Bakshi, HA
dc.contributor.author	Chellappan, DK
dc.contributor.author	Tambuwala, MM
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2021-04-09T03:58:33Z
dc.date.available	2020-05-29
dc.date.available	2021-04-09T03:58:33Z
dc.date.issued	2020-11
dc.identifier.citation	Drug development research, 2020, 81, (7), pp. 837-858
dc.identifier.issn	0272-4391
dc.identifier.issn	1098-2299
dc.identifier.uri	http://hdl.handle.net/10453/147944
dc.description.abstract	Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Wiley
dc.relation.ispartof	Drug development research
dc.relation.isbasedon	10.1002/ddr.21704
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.title	Hybrid molecules based on 1,3,5-triazine as potential therapeutics: A focused review.
dc.type	Journal Article
utslib.citation.volume	81
utslib.location.activity	United States
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2021-04-09T03:58:30Z
pubs.issue	7
pubs.publication-status	Published
pubs.volume	81
utslib.citation.issue	7

Abstract:

Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/147944